Search Orphan Drug Designations and Approvals
-
Generic Name: | durvalumab | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Imfinzi | ||||||||||||||||
Date Designated: | 01/15/2020 | ||||||||||||||||
Orphan Designation: | Treatment of hepatocellular carcinoma | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
AstraZeneca Pharmaceuticals LP 1800 Concord Pike Wilmington, Delaware 19803 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | durvalumab |
---|---|---|
Trade Name: | Imfinzi | |
Marketing Approval Date: | 10/21/2022 | |
Approved Labeled Indication: | In combination with tremelimumab-actl for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) | |
Exclusivity End Date: | 10/21/2029 | |
Exclusivity Protected Indication* : | treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-